Swiss pharma giant Roche RHHBY is expanding its obesity and metabolic disease pipeline through an exclusive worldwide licensing agreement with Rona Therapeutics for an investigational RNA interference (RNAi) candidate targeting activin receptor-like kinase 7 (ALK7). The deal reinforces Roche's focus on developing next-generation treatments for obesity, a market with growing demand for differentiated therapies. Year to date, shares of Roche have risen 4.3% compared with the industry's growth of 13%.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.